Market Place
Sourcing Support
SK Biopharmaceuticals Partners with ProEn on Oncology Research
16 Dec 2024 //
PR NEWSWIRE
SK BioPharma Seals Actinium-225 Research Deal with Korea Institute
18 Nov 2024 //
PR NEWSWIRE
SK Signs $572M Deal With Full-Life For Radiopharma Leadership
17 Jul 2024 //
FIERCE BIOTECH
Full-Life And SK Biopharm License Novel Solid Tumor Therapy
17 Jul 2024 //
PR NEWSWIRE
SK Bio Announces 100,000 Patients Have Been Treated with Cenobamate
11 Mar 2024 //
PR NEWSWIRE
Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC
12 Oct 2023 //
PR NEWSWIRE
SK Biopharma`s Proteovant Therapeutics Presents Preclinical Data on IKZF2
26 Sep 2023 //
PR NEWSWIRE
Korea`s SK Biopharma enters MENA through strategic partnership with Hikma
21 Aug 2023 //
BIOSPECTRUM ASIA
SK Bio Assembles `Board of Prominent Experts` to Boost Growth, Innovation
02 Aug 2023 //
PR NEWSWIRE
SK Biopharmaceuticals Makes Big Bets to be `Big Biotech`
17 Jul 2023 //
PR NEWSWIRE
SK Biopharmaceuticals to Present Future Plan for Global Investors
09 Jan 2023 //
PR NEWSWIRE
SK Biopharmaceuticals` Partner Angelini Pharma Launches Cenobamate in France
08 Dec 2022 //
PRNEWSWIRE
Seoul National University Bundang Hospital Presents Study of SK Biopharma`
05 Dec 2022 //
BIOSPACE
New Drug Filing for Cenobamate Accepted for Review in Canada and Israel
09 Aug 2022 //
PRNEWSWIRE
SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate
14 Jul 2022 //
PRNEWSWIRE
Long-Term Efficacy and Safety Data of XCOPRI CV Published in Neurology
22 Jun 2022 //
PRNEWSWIRE
SK Biopharmaceuticals’ revenue plunges 70% in Q1
12 May 2022 //
KOREABIOMED
SK life science to Present Latest XCOPRI CV Data at AAN 2022
24 Mar 2022 //
PRNEWSWIRE
SK Bio Becomes 1st Korean Company to Join Pharmaceutical Supply Chain Initiative
24 Feb 2022 //
PRNEWSWIRE
SK Biopharma, Biorchestra forge partnership for miRNA-targeted therapeutics
06 Jan 2022 //
PHARMABIZ
SK life science Initiates Phase 3 Clinical Trial of Carisbamate for LGS
06 Jan 2022 //
PRNEWSWIRE
BIORCHESTRA, SK Bio collaborate to develop miRNA-targeted therapeutics
04 Jan 2022 //
ASIAONE
SK Biopharm makes record-high IPO with $28.5-billion
04 Jan 2021 //
KOREABIOMED
SK Biopharma and LifeSci Venture Partners to push open innovation
04 Nov 2020 //
BIOSPECTRUMASIA
SK Biopharma and LifeSci Venture Partners to push open innovation
03 Nov 2020 //
BIOSPECTRUMASIA
SK Biopharmaceuticals and LifeSci Venture Partners Forge Ties
02 Nov 2020 //
PRNEWSWIRE
SK Biopharma and LifeSci Venture partners forge ties for open innovation
02 Nov 2020 //
BIOSPECTRUMASIA
SK Biopharma takes anti-seizure medication to Japan
15 Oct 2020 //
BIOSPECTRUMASIA
SK Biopharmaceuticals, Ono Enter Licensing Agreement for Cenobamate
13 Oct 2020 //
PRNEWSWIRE
SK Biopharma initiates Ph III trials for seizures drug in Asia
15 Sep 2020 //
BIOSPECTRUM ASIA
SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate
11 Sep 2020 //
PRNNEWSWIRE
SK life science Expands Support for the Epilepsy Foundation to Advance Epilepsy
15 Jul 2020 //
PRNEWSWIRE
SK Biopharmaceuticals set to make historic IPO
24 Jun 2020 //
INVESTORS
SK Biopharmaceuticals emerges from pandemic delays with pitch for $822M IPO
16 Jun 2020 //
ENDPTS
SK Biopharmaceuticals eyes W960b blockbuster IPO in July
14 Jun 2020 //
KOREAHERALD
SK Biopharmaceuticals Receives New Drug Development Awards
10 Jun 2020 //
BIOSPECTRUMASIA
SK Biopharmaceuticals Applies for Listing
20 May 2020 //
KOREABIZWIRE
EMAAccepts Arvelle Therapeutics` Marketing Authorization Application
26 Mar 2020 //
PRNEWSWIRE
SK Biopharmaceuticals CEO promises new drug every other year
20 Jan 2020 //
THE KORES HERALD
SK Biopharmaceuticals, preps for $850M IPO in January
27 Nov 2019 //
FIERCE PHARMA
FDA Approves XCOPRI® (cenobamate tablets)
21 Nov 2019 //
PR NEWSWIRE
Arvelle Acquires Exclusive Rights from SK Biopharmaceuticals` to Develop and Commercialize Cenobamate in EU
13 Feb 2019 //
BUSINESSWIRE
